atezolizumab + carboplatin + docetaxel + pertuzumab + trastuzumab

Atezoilzumab + carboplatin + docetaxel + pertuzumab + trastuzumab is a five-drug combination regimen composed of: - **Atezolizumab**: a monoclonal antibody PD-L1 checkpoint inhibitor that enhances anti-tumor immune response. - **Carboplatin**: platinum-based chemotherapy that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Docetaxel**: taxane chemotherapy that stabilizes microtubules and inhibits cell division. - **Pertuzumab**: monoclonal antibody targeting HER2 dimerization, inhibiting cell proliferation. - **Trastuzumab**: monoclonal antibody binding to HER2 extracellular domain, inhibiting downstream signaling and inducing antibody-dependent cellular cytotoxicity. This regimen is used in clinical trials and practice for HER2-positive breast cancer, especially advanced/metastatic or high-risk disease. Mechanism combines immune checkpoint inhibition, HER2 dual blockade, and cytotoxic chemotherapy, targeting distinct tumor cell vulnerabilities and microenvironment. Developers for atezolizumab include Genentech/Roche; carboplatin, docetaxel, pertuzumab, and trastuzumab are Roche/Genentech products. No universal brand name for this five-drug combination; commonly referenced using generic drug names in protocols.